Zacks.com on MSN1h
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival GoalAstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...
Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds ...
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...
BASKING RIDGE, N.J. & RAHWAY, N.J., September 17, 2024--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC. RAHWAY, N.J., September 18, 2024--Merck ...
(JAMA Network Open) A phase III trial of the antibody-drug conjugate patritumab deruxtecan in non-small cell lung cancer met the primary endpoint of progression-free survival, although two deaths not ...
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback